

## **Anxiety Explored: Understanding Classification, Effective Treatments, and the Healing Essence of Aromatherapy**

Soni RK<sup>1</sup>, Chauhan B<sup>2</sup>

<sup>1,2</sup>*Faculty of Pharmacy, The Maharaja University, Baroda, Vadodara*

*Received: 30<sup>th</sup> Mar 24; Revised: 20<sup>th</sup> Apr 24; Accepted: 24<sup>th</sup> May 24; Available Online: 25<sup>th</sup> Jun 24*

---

### **ABSTRACT**

This thorough literature review explores the complex field of anxiety, with particular attention to how it is classified, what kinds of treatments are available, and how aromatherapy and essential oils are becoming more and more important in managing anxiety. Anxiety disorders, which include everything from panic disorder and phobias to generalised anxiety disorder, constitute a substantial worldwide health burden. Complementary therapies are being investigated because traditional treatment options, which include psychotherapy, medicine, and lifestyle modifications, still have limits. Aromatherapy has gained attention for its potential to alleviate symptoms of anxiety. It is based on the therapeutic application of aromatic plant extracts. The classification of anxiety, traditional therapies, and the mechanisms underpinning aromatherapeutic interventions are all summarised in this review of recent studies. In order to give readers a thorough grasp of anxiety disorders, this review integrates psychology, pharmacology, and alternative medicine to examine the use of essential oils in anxiety management.

**Keywords:** Anxiety, Treatments, Aromatherapy, Essential oils.

---

### **INTRODUCTION**

Anxiety is a complex and common mental health disorder that has become more prominent in today's times. Anxiety can severely impair a person's performance in daily functions across various spheres of activity and well-being. It is defined by excessive fear, apprehension, and increased physiological reactivity. The first feature focuses on the diverse types and the multiple sets of reasons fear can develop from. The second feature analyses the relations between anxiety and the person's self, society, and surroundings. The third feature pays attention to the consequences of multiple cases of anxiety and illness.

The Latin word "anxietas" (to choke, throttle, trouble, and upset) is the source of the English word "anxiety," which refers to a range of behavioural, affective, and cognitive reactions to perceived danger. It's normal for humans to feel anxious. When anxiety is controlled, it can help people respond predictably and adaptively to difficult or stressful situations.

When anxiety levels are too high, people become unstable and enter a dysfunctional state. When anxiety develops in the absence of a challenge or stress, when it lasts longer or is more severe than the challenge or stress, when it causes a great deal of distress, and when it impairs psychological, social, occupational, biological, or other aspects of one's life, it is deemed excessive or pathological.[1]

Because poor mental health has major social and economic ramifications, there has been a recent emphasis on the need to promote wellbeing and positive mental health in order to prevent the development of mental disorders.[2-4] Additionally, research indicates that, both at the societal and individual levels, mental health promotion and preventative interventions are cost-effective in preventing or lowering morbidity associated with mental illness.[5-6]

### **Fact and Statistics**

The National Mental Health Survey (NHMS)

The 2015-16 National Mental Health Survey in India revealed that 15% of the population requires proactive assistance for stress or anxiety-related disorders, affecting over 40 million people, a significant number.

A 2017 Lancet study revealed 197 million mental health disorders in India, with depression being the most prevalent, affecting 45.9 million people. Anxiety, affecting 44.9 million, affected 3.3% of the population. Kerala had the highest prevalence of anxiety.

The COVID-19 pandemic significantly impacted global mental health, with a 25% increase in anxiety and depression prevalence, and a 35% rise in anxiety disorders in India, particularly affecting women and younger people.[7]

The inability to control worry and excessive anxiety and concern for at least six months are diagnostic criteria.

Three or more of the following symptoms have been present for at least six months in conjunction with the anxiety: restlessness, feeling tense or agitated, being easily tired, having trouble focusing or having a blank mind, irritability, muscle tension, disturbed sleep, and irritability.[8-9]

**Clinical Manifestations**

Anxiety disorders often involve personal unease, focus issues, sleep problems, and social or professional functioning issues. These disorders differ in presentation, progression, and management.

Physical health complaints can distract from underlying anxiety symptoms, particularly in panic disorder, which involves extreme fear, impending doom, and physical symptoms like breathlessness, dizziness, and chest pain.[10]

The physical effects of anxiety on your body may manifest as:

- A sensation of churning in your stomach
- Light-headedness or dizziness
- Tingling sensations like pins and needles
- Restlessness or an inability to remain seated
- Headaches, backaches, or various other aches and pains
- Increased breathing rate
- Rapid, irregular, or pounding heartbeat
- Sweating or experiencing hot flushes
- Difficulty sleeping
- Grinding of teeth, particularly during nighttime
- Nausea or feelings of sickness

- Altered frequency of urination or bowel movements
- Changes in libido
- Occurrence of panic attacks.

The psychological effects of anxiety on your mind may encompass:

- Feelings of tension, nervousness, or an inability to relax
- A pervasive sense of dread or anticipating the worst outcomes
- Perceiving the world as either accelerating or decelerating
- Sensation of being scrutinized by others due to anxiety
- Inability to cease worrying or fearing negative consequences if worry ceases
- Concerns about experiencing anxiety-related symptoms, such as panic attacks
- Seeking excessive reassurance from others or fearing their displeasure
- Fearing detachment from reality
- Experiencing a dip in mood leading to depression
- Rumination, where one dwells extensively on negative experiences or situations
- Depersonalization, a form of dissociation where one feels disconnected from their mind or body, akin to observing oneself in a movie
- Derealization, another form of dissociation characterized by feeling disconnected from the surrounding world or questioning its reality
- Preoccupation with potential future events, commonly known as anticipatory anxiety.[11]

**Table 1: The categorization of neurotic and anxiety disorders as outlined in the American Psychiatric Association's Diagnostic and Statistical Manuals of Mental Disorders [12]**

DSM-I Psychoneurotic Disorders (1952)	DSM-II Neuroses (1968)	DSM-III Anxiety Disorders (1980)	DSM-III-R Anxiety Disorders (1987)	DSM-IV Anxiety Disorders (1994)
Phobic reaction	Phobic Neurosis	Agoraphobia with Panic Attacks Agoraphobia without Panic Attacks Social Phobia Simple Phobia	Agoraphobia without history of Panic Attacks Social Phobia Simple Phobia	Agoraphobia without history of Panic Attacks Social Phobia Simple Phobia
Anxiety reaction	Anxiety Neurosis	Panic Disorder Generalized Anxiety Disorder	Panic Disorder with Agoraphobia Panic Disorder without Agoraphobia Generalized Anxiety Disorder	Panic Disorder with Agoraphobia Panic Disorder without Agoraphobia Generalized Anxiety Disorder
Obsessive Compulsive Reaction	Obsessive Compulsive Neurosis	Obsessive- Compulsive	Obsessive- Compulsive Disorder	Obsessive- Compulsive

		Disorder Posttraumatic Stress Disorder	Posttraumatic Stress Disorder	Disorder Posttraumatic Stress Disorder Acute stress disorder
Depressive Reaction	Depressive Neurosis			
Conversion Reaction	Hysterical Neurosis			
Dissociative reaction	Neurasthenic Neurosis Hypochondriacal Neurosis, Depersonalization Neurosis			

Anxiety can manifest in various ways. If your symptoms align with specific criteria, your doctor may diagnose you with a particular anxiety disorder. Here are some frequently diagnosed anxiety disorders:

- Generalized Anxiety Disorder (GAD) entails experiencing frequent or uncontrollable concerns about various aspects of your daily life. Due to the multitude of potential anxiety symptoms, this diagnosis can be broad, leading to individual experiences of GAD varying significantly from person to person.
- Social Anxiety Disorder, or social phobia, is characterized by experiencing intense fear or anxiety specifically in social situations, such as parties, workplaces, or ordinary interactions where communication with others is necessary. Refer to our section on types of phobia for further details.
- Panic Disorder refers to experiencing regular or frequent panic attacks without a discernible cause or trigger. Living with panic disorder can entail a constant fear of experiencing another panic attack, to the extent that this fear itself can precipitate panic attacks. For additional information, please see our section on panic attacks.
- Phobias having panic attacks on a regular or frequent basis without any obvious trigger or cause is known as panic disorder. A persistent fear of having another panic attack can be a defining feature of living with panic disorder, to the point where the fear can trigger panic attacks. Please refer to our section on panic attacks for more details.
- Post-Traumatic Stress Disorder (PTSD) is a diagnosis typically given to individuals who develop anxiety-related issues following a traumatic experience. PTSD may entail experiencing flashbacks or nightmares that make you feel as though you are reliving the fear and

anxiety you felt during the traumatic events. For further information, please refer to our resource on PTSD and complex PTSD.

- Obsessive-Compulsive Disorder (OCD) is a diagnosis you might receive if your anxiety issues involve repetitive thoughts, behaviours, or urges. For additional information, please consult our resource on OCD.[11]
- Agoraphobia is a persistent fear of challenging or embarrassing situations, often causing functional impairment. It typically lasts for six months or more and can occur in public transportation, open spaces, crowds, or alone. Individuals with agoraphobia often avoid these situations, seek support, or endure intense fear. If left untreated, it can escalate to house boundness. Agoraphobia is diagnosed when the fear causes significant distress or interferes with daily activities.
- Selective mutism is a condition where children do not speak in social situations they are expected to, such as school, despite speaking in other situations. This lack of speech can interfere with social communication and can lead to academic problems and social isolation. Children with selective mutism may also experience excessive shyness, fear of social embarrassment, and high social anxiety. Typically beginning before age 5, selective mutism may not be formally identified until school. Some children may outgrow selective mutism, while symptoms of social anxiety disorder may remain.[13]

**Treatment Options Available**

1. Cognitive–Behavioural Therapy and Medications
2. Exposure therapy
3. Acceptance and commitment therapy (ACT): This type of therapy uses strategies of living in the moment and refraining from judgment, along with behaviour change, to cope with anxiety.
4. Dialectical behavioural therapy (DBT): DBT combines CBT techniques with meditation concepts.

5. Interpersonal therapy: This is short-term supportive talk therapy that focuses on resolving interpersonal (or relational) problems.[14]
6. Pharmacological Therapy/ Medication:
  - Selective Serotonin Reuptake Inhibitor/ Antidepressants
  - Serotonin–Norepinephrine Reuptake Inhibitors
  - Benzodiazepines/ Anti-anxiety medications
  - Antiseizure Medications
  - Tricyclic Antidepressants
  - Beta blockers
  - Additional Medications
7. Experimental and Off-Label Nonpharmacological Treatments:
  - Electroconvulsive Therapy
  - Vagal Nerve Stimulation
  - Surgery
  - Deep-Brain Stimulation
8. Complementary and Alternative Medicine / Traditional therapy:
  - yoga
  - meditation
  - aromatherapy
  - massage
  - herbal treatments
  - Bach flower remedies
  - Exercise
  - Relaxation techniques
  - Biofeedback
  - Hypnosis [15-16]

#### **Exploring the Preference for Alternative Therapies in Managing Anxiety: A Question of Medication Choice:**

There are several reasons why some people may choose complementary therapies over conventional medication for treating anxiety or depression-like symptoms:

1. Preference for natural approaches: Some individuals prefer natural or holistic treatments over conventional medication due to concerns about potential side effects or the use of synthetic compounds.
2. Desire for a holistic approach: Complementary therapies often focus on treating the whole person, addressing mental, emotional, and physical aspects of health, which can be appealing to those seeking a more comprehensive approach to wellness.
3. Belief in the efficacy of complementary therapies: Many people believe in the effectiveness of complementary therapies based on personal experiences, anecdotal evidence, or cultural beliefs.
4. Perception of fewer side effects: Complementary therapies are often perceived as having fewer

side effects compared to conventional medications, leading some individuals to prefer them as a safer alternative.

5. Preference for self-management: Some individuals prefer therapies that empower them to take an active role in their own healing process, such as meditation, yoga, or acupuncture, rather than relying solely on medication prescribed by a healthcare professional.
6. Cultural or religious beliefs: Certain cultural or religious beliefs may influence individuals to choose complementary therapies that align with their cultural or spiritual practices.
7. Accessibility and affordability: In some cases, complementary therapies may be more accessible or affordable than conventional medication, particularly for individuals without health insurance or limited financial resources.

It's essential to note that while complementary therapies may offer benefits for some individuals, they may not be suitable or effective for everyone, and they should not be used as a substitute for evidence-based medical treatments. It's important for individuals to consult with a healthcare professional to discuss their treatment options and develop a personalized plan that addresses their specific needs and preferences.

#### **Aromatherapy**

Aromatherapy is a complementary therapy that uses essential oils extracted from plants to promote mental, emotional, and spiritual well-being. These highly concentrated oils are used topically, diluted into a low concentration solid oil, for contact therapy and respiratory and papillary therapy. However, they may cause skin sensitization, contact dermatitis, and phototoxicity, so dilution is necessary. Essential oils are extracted from the entire plant, including bark, roots, flowers, leaves, seeds, and resins.

Aromatherapy is a one-on-one consultation between a therapist and patient, where the patient's medical and lifestyle history is discussed. A customised plant blend is prepared, focusing on safety, dosage, cultural customs, and therapeutic qualities.

The therapy can be administered through massage or inhaled blends. Aromatherapy is crucial for its therapeutic benefits and has been shown to provide "immeasurable comfort" to dialysis patients. [17,18]

Clinical studies explore the function of the smell reaction after inhaling essential oils. Volatile molecules trigger an olfactory pathway nerve impulse, which is processed by the amygdala and hippocampal regions. Odor-induced memories and

positive associations have been linked to improved mood, health, and wellbeing. Aromatherapy may also interact with the autonomic nervous system to promote calmness and lower stress levels.[19-23]

Over the past 30 years, aromatherapy has grown as a clinical practice that uses massage and inhalation to provide complementary therapy in clinical settings.

A growing number of clinical studies have examined aromatherapy's potential as a non-pharmacological intervention.[24-27] While treating patients' illnesses is the primary focus of healthcare professionals, they are also recognising more and more that supporting patients' psychological wellbeing requires a patient-centered approach[28-29]. An essential oil's aromatic compounds may have sedative and anxiolytic properties, according to mounting research [30]. Certain essential oils have been found in studies to help lower anxiety and provide easy-to-use, low-risk, affordable treatments that enhance patient outcomes overall.[31-33]

Since ancient times, essential oils (EOs) have been utilised as medicinal agents because of their pharmacological and psychological properties. These volatile odour compounds have been used for a variety of purposes in ancient Egypt, India, Persia, Mesopotamia, and China. They are composed of benzenoids, phenylpropanoids, monoterpenoids, and sesquiterpenoids. The biological effects of EOs, such as their antimicrobial, antifungal, antiviral, anti-inflammatory, antioxidant, anticancer, and antinociceptive qualities, have been researched. Research has demonstrated that EOs elicit a variety of pharmacological reactions in the nervous system, which may help treat mental health conditions like dementia, anxiety, and depression. EOs are used in aromatherapy, a well-liked complementary therapy, to treat anxiety, depression, insomnia, and cognitive disorders.[34] Summary of preclinical and clinical investigations examining the impact of essential oils (EOs) on the nervous system and their potential as antidepressants and anxiolytics.

**Table 2:**

<b>Botanical name of plant source/EO name. Major and active compounds of Eos</b>	<b>Animal model/test subjects</b>	<b>Route of administration</b>	<b>Effect</b>	<b>References</b>
<i>Boswelliasp</i> (frankincense) $\alpha$ -Pinene, limonene, $\alpha$ -thujene, myrcene, sabinene, Para-cymene	Sleep-deprived adult male Sprague–Dawley rats	Topical administration	Antidepressant/anxiolytic	[35]
<i>Canangaodorata</i> (Ylang-ylang) Benzyl benzoate, linalool and benzyl alcohol	Healthy volunteers or Mice	Olfactory Or Transdermal application	Antidepressant/anxiolytic	[36-42]
<i>Cinnamomumverum</i> (cinnamon) TCA	Male albino mice	i.p injection	Antidepressant/anxiolytic	[43]
<i>Citrus aurantium</i> (Neroli) Limonene, $\beta$ -myrcene, and $\beta$ -pinene	Gerbins or healthy postmenopausal women or woman in labor	Olfactory	Anxiolytic/Antidepressant	[44-46]
<i>Citrus bergamia</i> (bergamot) Limonene, linalyl acetate and linalool	Male Wistar rats or healthy women or volunteers	i.p injection or Olfactory	Antidepressant/anxiolytic	[47-51]
<i>Citrus sinensis</i> (sweet orange) d-limonene, $\beta$ -myrcene, $\alpha$ -pinene, sabinene, linalool, geranial, and neral	Patients/ men healthy volunteers/ Male Wistar rats	Olfactory	Antidepressant/anxiolytic	[52-54]

<i>Cymbopogon citratus</i> (lemongrass) Neral, geranial and $\beta$ -myrcene	Male Swiss mice/ Forty men	Olfactory	Antidepressant/anxiolytic	[55-57]
<i>Lavandula angustifolia</i> (lavender) Linalyl acetate, linalool, lavandulyl acetate, myrcene, terpinen-4-ol, -terpineol, cis-linalool oxide, trans-linalool oxide and ocimene	Healthy volunteer or Mongolian gerbil or patients	Oral or Olfactory or	Antidepressant/anxiolytic	[58-60]
<i>Citrus paradisi</i> (grapefruit) Limonene, R-terpinene, R-pinene	Patients undergoing colonoscopy	Olfactory	Antidepressant/anxiolytic	[61]
<i>Pelargonium graveolens</i> (geranium) b-citronellol, citronellylformate, geraniol, 10-epi-g-cudesmol, geranylformate and (l)-linalool	Patients with acute myocardial infarction/ nulliparous women	Olfactory	Antidepressant/anxiolytic	[62-63]
<i>Rosa damascena</i> (rose) 2-phenethyl alcohol, citronellol, geraniol, methyl eugenol and eugenol	Healthy volunteer/ Male Wistar rats/ Gerbils	Olfactory/ Transdermal application	Antidepressant/anxiolytic	[64-67]
<i>Rosmarinus officinalis</i> (rosemary) Cineole, camphor, $\alpha$ -pinene, camphene and $\alpha$ -terpineol	Mice	Olfactory	Antidepressant/anxiolytic	[68]
<i>Salvia sclarea</i> (Clary sage) Linalool, $\alpha$ -terpineol, geraniol, acetate derivative of geraniol, and myrcene	Mice/ Sprague-Dawley rats/	i.p injection/ Olfactory	Antidepressant/anxiolytic	[69-70]

The anti-CI (cognitive impairment) effects and mechanisms of essential oils extracted from natural plants. [71]

**Table 3:**

Source plant	Active ingredients	Effects and mechanisms
<i>Ligusticum chuanxiong</i> hort	Senkyunolide A; Ligustilide	Significantly reducing the levels of MAO and AchE in the brain of VCI mice; inhibiting the proliferation of BV-2 cells and reducing the increase of inflammatory factors TNF- $\alpha$ , NO levels.
<i>Coriandrum sativum</i> var.	Linalool (69.358%); $\gamma$ -terpinene (7.729%); $\alpha$ -pinene (6.509%)	Decreasing SOD and LDH specific activities, increasing GPX specific activity and attenuating the increased MDA level, Provides neuroprotection by alleviating oxidative stress induced by A $\beta$ 1-42 injection; reducing amyloid deposits in the hippocampus.
<i>Angelica sinensis</i> (Olive.) Diels		Promoting the expression of neuron-protective Bcl-2 protein, reducing the

		expression of apoptotic Bax protein in brain tissue, thereby inhibiting neuronal apoptosis and accelerating the recovery of neurological function.
<i>Cinnamomum cassia</i> Presl	phenylallyl compounds	Inhibiting the increase of COX activity and increasing the release of prostaglandin E2, thus improving the memory function of APP transgenic AD mice.
<i>Thymus vulgaris</i> L.	Thymol (42.10%); cymene (19.20%); $\beta$ -caryophyllene (6.40%); Carvacrol (2.70%); $\alpha$ -Pinene (1.52%)	Anti-oxidative stress and inhibition of AChE activity.
<i>Chimonanthus nitens</i> Oliv. leaves		Increasing SOD activity and decreasing MDA content, thereby reducing the damage to the organism from oxidative stress, as well as the extent of neuronal cell damage in the CA1 region of the hippocampus.
<i>Magnolia denudate</i> Desr.		Improving the learning memory behavior and increasing the expression of 5-HT and DA proteins in ASD model rats, the mechanism may be related to the excitability of olfactory transmission pathways and functional brain regions such as hippocampus, amygdala and hypothalamus, as well as the plasticity of neural circuitry.
Citrus $\times$ limon (Linnaeus) Osbeck		decreasing neuronal loss, improving learning and memory ability in APP/PS1 mice after neurodegeneration, suppressing accumulation of amyloid protein, downregulating AChE activity in the hippocampus and Enhancing synaptic plasticity by increasing BDNF, PSD95 and synaptophysin to improve memory levels.
<i>Schisandrachinensis</i> Baill.	$\beta$ -Terpinene (19.50%); 1R- $\alpha$ -pinene (3.60%); Benzene,1-methyl-2-(1-methylethyl) (4.63%); Terpinen-4-ol (4.92%); Benzene,2-methoxy-4-methyl-1-(1-methylethyl) (4.57%); Nerolidol (6.71%); (-)-g-Cadinene (4.32%)	Improving the activities of SOD, MDA, GSH-Px.
<i>Schisandrachinensis</i> (Turcz.) Baill.		Inhibiting the activation of NF- $\kappa$ B/MAPK pathway activation, reducing the phosphorylation of p-38 and attenuating the release of pro-inflammatory cytokines IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , as well as improving microglia activation.
<i>Tetraclinis articulata</i>	camphor (14.52%); $\alpha$ -pinene (22.68%); L-bornyl acetate (16.87%); borneol (5.2%);	Increasing the activity levels of SOD, CAT and GPX in hippocampal tissue, significantly ameliorating the A $\beta$ 1-42-

	limonene (7.34%)	induced decrease in GSH levels and increasing MDA, thereby reducing oxidative stress in the rat hippocampus to ameliorate the memory deficit induced by A $\beta$ 1-42 treatment.
<i>Pinushalepensis</i>	beta-caryophyllene (29.45%); pinene (11.14%); myrcene (7.85%); terpinolene (3.90%); 2-phenylethylisovalerate (10.38%); alpha-humulene (6.49%)	Inhibiting of AChE activity and reducing oxidative damage in rat hippocampus.
<i>Chamaecyparisohtusa</i> Sieb. & Zucc.	$\alpha$ -terpinyl acetate (16.82%); $\beta$ -phellandrene (13.11%); $\beta$ -myrcene (5.68%); limonene (6.49%); bornyl acetate (7.48%); $\gamma$ -terpinene (4.28%); $\alpha$ -terpineol (4.33%); elemol (6.22%); thujopsene (4.50%); $\beta$ -eudesmol (4.13%); beyerene (3.35%)	Inhibiting neuronal apoptosis and AChE activity.
<i>Rosa rugosa</i> Thunb.	6-Octen-1-ol,3,7-dimethyl-,(R)-(+)-Citronellol (54.02%); 2,6-Octadien-1-ol,3,7-dimethyl-,(E)-trans-Geraniol (15.01%)	Suppressing A $\beta$ deposits and reducing the A $\beta$ oligomers to alleviate the toxicity induced by A $\beta$ overexpression, activating the expression of GST-4 gene, which may act through SKN-1 signaling pathway.
<i>Zataria multiflora</i> Boiss.		Antioxidant, anti-inflammatory and anticholinesterase activity.
<i>Lavandula angustifolia</i> Mill.	Linalool (33.1%); linalyl acetate (10.4%); 1,8-cineole (8.0%); borneol (4.5%)	Protecting cells free from A $\beta$ 1-42 oligomer-induced molecular damage, inhibiting activation of the pro-apoptotic enzyme caspase-3 and the increase of intracellular ROS; inhibiting the AChE activity; exerting anti-oxidative stress effects.
<i>Rosmarinus officinalis</i>	$\alpha$ -pinene (11.1%); camphene (4.8%); $\beta$ -pinene (6.4%); 1,8-cineole (46.0%); camphor (10.8%); borneol (2.8%); (E)-caryophyllene (3.0%)	Producing a significant improvement in the rate of spontaneous alternation behavior, activating of CNS to improve cognitive function.
<i>Thymus vulgaris</i> L.	Thymol (42.10%); p-cymene (19.20%); $\beta$ -caryophyllene (6.40%); Carvacrol (2.7%).	Ameliorating Sco-induced increasing of AChE activity, amnesia, anxiety, and reducing the brain antioxidant capacity.
<i>Mentha piperita</i> Linn.	Menthol (45.56%); menthone (20.9%); menthol acetate (6.64%); 1,8-cineole (4.77%); new menthol (3.27%); iso-menthone (3.08%); menthofuran (2.05%); $\beta$ -caryophyllene (1.79%); limonene (1.48%); pulegone (1.31%); germacrene D (1.17%)	Reducing A $\beta$ deposits in the brain, protecting neuronal cells and restoring them to their normal state, and reducing peroxidative damage to brain tissue, it may improve cognitive function in AD by regulating arginine and proline metabolism, inositol phosphate metabolism, and cysteine and methionine metabolism.
<i>Alpinia Oxyphylla</i> Miq.	1,2,4,5-tetramethylbenzene (42.96%); myrtenal (4.66%); linalool (4.34%); (-)-4-	Regulating the activity of ACh synthase and catabolic enzymes, improving the antioxidant capacity of the body, up-

	terpineol (2.96%); g-terpinene (2.21%); (+)-nootkatone (1.48%); $\beta$ -pinene (1.32%); (+)-(4R)-limonene (1.25%); (1S)-(+)-3-carene (1.02%)	regulating the expression of BDNF, ERK, CREB, Bcl-2 and other genes and proteins p-ERK1/2 and p-AKT473, and down-regulating the expression of Bax and caspase-3 proteins, the mechanism of which may be related to the regulation of hippocampal neuronal apoptosis.
<i>Punicagranatum</i> L.		Reducing accumulation of A $\beta$ and p25, a calpain product, and increasing expression of COX IV-1, a key mitochondrial enzyme.
<i>Acorustatarinowii</i> Schott	$\beta$ -asarone (54.62%); $\alpha$ -asarone (32.34%)	Inhibiting the conversion of A $\beta$ 25-35 from $\alpha$ -helix to $\beta$ -fold and affecting its secondary structure, thus preventing A $\beta$ aggregation and fibril formation; increasing ChAT levels, decreasing GFAP expression and protecting neurons in hippocampal tissue; reducing the deposition of misfolded A $\beta$ and polyQ proteins and improving serotonin sensitivity and olfactory learning skill in worms, its maintenance of protein homeostasis depends on an autophagic pathway regulated in part by the hsf-1 and sir-2.1 genes.
SuHeXiang Wan Essential Oil	Benzyl Benzoate (29.87%); isobutyl cinnamate (3.05%); 17-oxygen lupinine (2.80%); Benzylcinnamic acid (2.53%); caryophyllene (2.42%); acetophenonepropyl ester (1.83%); Benzyl acetate (1.71%)	Inhibiting A $\beta$ -induced apoptosis and ROS production by upregulating HO-1 and Nrf2 expression; inhibiting A $\beta$ -induced Tau phosphorylation by inhibiting JNK and p38 activation in the brain; promoting Bcl-2 expression and inhibiting Bax expression thereby inhibiting apoptosis.
<i>Listeacubeba</i> (Lour.) Persoon	d-limonene (14.15%); $\beta$ -myrcene (3.04%); methylhepteneone (2.15%); geranial (31.74%); neral (30.94%)	Inhibiting levels of oxidative stress (including MDA and phosphorylated tau protein) in the brain and preventing brain atrophy.
Essential Oil Mix	Limonene (91.11%); $\gamma$ -terpinene (2.02%); $\beta$ -myrcene (1.92%); $\beta$ -pinene (1.76%); $\alpha$ -pinene (1.01%); sabinene (0.67%); linalool (0.55%); cymene (0.53%); valencene (0.43%)	Restoring the activity of the cholinergic system and the antioxidant status of the brain.

## CONCLUSION

In conclusion, anxiety is a complex and prevalent mental health condition that can significantly impact individuals' well-being. Understanding its various classifications and treatment options is crucial for effectively managing symptoms and improving quality of life. Conventional treatments such as medication and therapy offer evidence-based approaches that have proven effective for many individuals. Additionally,

complementary therapies like aromatherapy with essential oils have gained attention for their potential benefits in reducing anxiety symptoms.

Aromatherapy with essential oils presents a promising adjunctive therapy for anxiety management, with research suggesting potential therapeutic effects on mood and stress levels. However, further studies are needed to better understand the mechanisms of action and efficacy of aromatherapy in treating anxiety disorders.

Overall, a holistic approach that integrates conventional treatments with complementary therapies like aromatherapy may offer individuals a comprehensive and personalized strategy for managing anxiety. It is essential for individuals to work closely with healthcare professionals to explore treatment options and develop a tailored plan that meets their unique needs and preferences. Through ongoing research and collaboration between healthcare providers and individuals experiencing anxiety, we can continue to advance our understanding and improve outcomes in anxiety treatment.

#### REFERENCES

1. Trivedi JK, Gupta PK. An overview of Indian research in anxiety disorders. *Indian Journal of Psychiatry* 2010; 52(1):S210-S2188.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. *Global Burden of Disease and Risk Factors*. Washington, DC: World Bank, 2006.
3. World Health Organization. WHO European Ministerial Conference on Mental Health (1st : 2005 : Helsinki F, World Health Organization. Regional Office for Europe. Mental health action plan for Europe : facing the challenges, building solutions. In: First WHO European Ministerial Conference on Mental Health, Helsinki, Finland. (EUR/04/5047810/7) 2005.
4. Green Paper. Improving the Mental Health of the Population Towards a Strategy on Mental Health for the European Union. Brussels, 30.
5. Cuijpers P, Van Straten A, Smit F. Preventing the incidence of new cases of mental disorders: a meta-analytic review. *The Journal of Nervous and Mental Disease*. 2005; 193(2):119– 25.
6. Singh V, Kumar A and Gupta S (2022) Mental Health Prevention and Promotion—A Narrative Review. *Frontier in Psychiatry* 2022; 13:1-17.
7. Koranne D. Latest Statistics of Anxiety Disorders in India.
8. Munir S, Gondal AZ, Takov V. Generalized anxiety disorder. 2019.
9. Adwas AA, Jbireal JM, Azab AE Anxiety: Insights into Signs, Symptoms, Etiology, Pathophysiology and Treatment. *East African Scholars Journal of Medical Sciences* 2019;2(10):580-591.
10. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. *Archives of General Psychiatry* 1989;46(11):984-992.
11. <https://www.mind.org.uk/media/7089/anxiety-and-panic-attacks-2021-pdf-version.pdf> available online: 04/2024. © Mind 2021.
12. Stein MB, Steckler T. *Behavioral Neurobiology of Anxiety and Its Treatment*. Springer Heidelberg Dordrecht, London, New York, 2010; 4-6.
13. Article published by American Psychiatric Association. *Psychiatry.org - What are Anxiety Disorders?* <https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders> Available online : 23/04/2024.
14. Johnson J, Herndon J. *The 333 Rule for Anxiety and Other Coping Strategies*. 2022.
15. Smith M, Segal J. *Therapy for Anxiety Disorders*.2024. <https://www.helpguide.org/articles/anxiety/therapy-for-anxiety-disorders.htm>
16. Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current Diagnosis and Treatment of Anxiety Disorders. *P&T* 2013; 38(1):30-57.
17. Stringer J, Donald G. Aromasticks in cancer care: an innovation not to be Sniffed at, *Complementary Therapies in Clinical Practice* 2011; 17(2): 116-121.
18. Lee S. The use of aromatherapy in the dialysis setting as a comfort measure. *Hemodialysis International* 2017; 21(1):A21.
19. Herz RS, The role of odor-evoked memory in psychological and physiological health. *Brain Sciences* 2016; 6(3):1-13.
20. Dyer J, Cleary L, Ragsdale-Lowe M, McNeill S, Osland C. The use of aromasticks at a cancer centre: a retrospective audit. *Complementary Therapies Clinical Practice* 2014; 20(4):203– 206.
21. Dobetsberger C, Buchbauer G. Actions of essential oils on the central nervous system: an updated review. *Flavour and Fragrance Journal* 2011; 26 (5):300–316.
22. Lin PH, Lin YP, Chen KL, Yang SY, Shih YH, Wang PY. Effect of aromatherapy on autonomic nervous system regulation with treadmill exercise induced stress among adolescents. *PLOS ONE* 2021; 16(4): e0249795.
23. Schneider R. Direct application of specially formulated scent compositions (AromaStick®) prolongs attention and enhances visual scanning speed. *Applied Cognitive Psychology* 2016; 30(4):650–654.
24. Hedigan F, Sheridan H, Sasse A. Benefit of inhalation aromatherapy as a complementary treatment for stress and anxiety in a clinical setting – A systematic review. *Complementary Therapies in Clinical Practice*2023; 52:101750.
25. Ball EL, Owen-Booth B, Gray A, Shenkin SD, Hewitt J, McCleery J. Aromatherapy for dementia. *Cochrane Database Systemic Reviews* 2020; 8:CD003150.
26. Boehm K, Büssing A, Ostermann T. Aromatherapy as an adjuvant treatment in cancer

- care-a descriptive systematic review. *African Journal of Traditional, Complementary and Alternative Medicine* 2012; 9(4):503–518.
27. Farahani MA, Afsargharehbagh R, Marandi F, Moradi M, Hashemi SM, Moghadam MP, Balouchi A. Effect of aromatherapy on cancer complications: a systematic review. *Complementary Therapies in Medicine* 2019; 47:102169.
  28. Gong M, Dong H, Tang Y, Huang W, Lu F. Effects of aromatherapy on anxiety: a meta-analysis of randomized controlled trials. *Journal of Affective Disorders* 2020; 274:1028–1040.
  29. Pearson ACS, Cutshall SM, Hooten WM, Rodgers NJ, Bauer BA, Bhagra A. Perspectives on the use of aromatherapy from clinicians attending an integrative medicine continuing education event. *BMC Complementary Alternative Medicine* 2019; 19(1):174.
  30. Mannucci C, Calapai F, Cardia L, Inferrera G, D'Arena G, Di Pietro M, Navarra M, Gangemi S, Spagnolo EV, Calapai G. Clinical pharmacology of citrus aurantium and citrus sinensis for the treatment of anxiety. *Evidence-based Complementary and Alternative Medicine* 2018; 2018:1-19.
  31. Kang HJ, Nam ES, Lee Y, Kim M. How strong is the evidence for the anxiolytic efficacy of lavender?: systematic review and meta-analysis of randomized controlled trials. *Asian Nursing Research* 2019; 13(5):295–305.
  32. Salehi-Pourmehr H, Ostadrahimi A, Ebrahimpour-Mirzarezaei M, Farshbaf-Khalili A. Does aromatherapy with lavender affect physical and psychological symptoms of menopausal women? A systematic review and meta-analysis. *Complementary Therapies Clinical Practice* 2020; 39:101150.
  33. Schneider R, Singer N, Singer T. Medical aromatherapy revisited-basic mechanisms, critique, and a new development. *Human Psychopharmacology: Clinical and Experimental* 2019; 34(1):e2683.
  34. Lizarraga-Valderrama LR. Effects of essential oils on central nervous system: Focus on mental health. *Phytotherapy Research*. 2021;35(2):657–679.
  35. Okano S, Honda Y, Kodama T, Kimura M. The effects of frankincense essential oil on stress in rats. *Journal of Oleo Science* 2019; 68(10):1003–1009.
  36. Moss M, Hewitt S, Moss L, Wesnes K. Modulation of cognitive performance and mood by aromas of peppermint and ylang-ylang. *International Journal of Neuroscience* 2008; 118(1): 59–77.
  37. Hongratanaworakit T, Buchbauer C. Evaluation of the harmonizing effect of ylang-ylang oil on humans after inhalation. *Planta Medica* 2004; 70(7): 632–636.
  38. Hongratanaworakit T, Buchbauer G. Relaxing effect of ylang-ylang oil on humans after transdermal absorption. *Phytotherapy Research* 2006; 20(9):758–763.
  39. Jung DJ, Cha JY, Kim SE, Ko IG, Jee YS. Effects of Ylang-Ylang aroma on blood pressure and heart rate in healthy men. *Journal of Exercise Rehabilitation* 2013; 9(2):250–255.
  40. Pujiarti R, Ohtani Y, Widowati TB, Kasmudjo W, Herath NK, Wang CN. Effect of *Melaleuca leucadendron*, *Cananga odorata* and *Pogostemon cablin* oil Odors on human physiological responses. *Wood Research Journal* 2012; 3(2):100–105.
  41. Zhang N, Zhang L, Feng L, Yao L. *Cananga odorata* essential oil reverses the anxiety induced by 1-(3-chlorophenyl) piperazine through regulating the MAPK pathway and serotonin system in mice. *Journal of Ethnopharmacology* 2018; 219:23–30.
  42. Zhang N, Zhang L, Feng L, Yao L. The anxiolytic effect of essential oil of *Cananga odorata* exposure on mice and determination of its major active constituents. *Phytomedicine* 2016; 23(14): 1727–1734.
  43. Sohrabi R, Pazgoohan N, Seresht HR, Amin B. Repeated systemic administration of the cinnamon essential oil possesses anti-anxiety and anti-depressant activities in mice. *Iranian Journal of Basic Medical Sciences* 2017; 20(6):708–714.
  44. Chen YJ, Cheng F, Shih Y, Chang TM, Wang MF, Lan SS. Inhalation of neroli essential oil and its anxiolytic effects. *Journal of Complementary and Integrative Medicine* 2018; 5(1): 1–10.
  45. Choi SY, Kang P, Lee HS, Seol GH. Effects of inhalation of essential oil of *Citrus aurantium* L. var. Amara on menopausal symptoms, stress, and Estrogen in postmenopausal women: A randomized controlled trial. *Evidence-based Complementary and Alternative Medicine* 2014; 2014:796578, 1–7.
  46. Namazi M, Akbari AAS, Mojab F, Talebi A, Majd AH, Jannesari S. Effects of *Citrus aurantium* (bitter Orange) on the severity of first-stage labor pain. *Iranian Journal of Pharmaceutical Research* 2014; 13(3): 1011–1018.
  47. Morrone LA, Rombolà L, Pelle C, Corasaniti MT, Zappettini S, Paudice P, Bonanno G, Bagetta G. The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippocampus of rat: Implication of monoterpene

- hydrocarbons. *Pharmacological Research* 2007; 55(4):255–262.
48. Rombolá L, Corasaniti MT, Rotiroti D, Tassorelli C, Sakurada S, Bagetta G, Morrone LA. Effects of systemic administration of the essential oil of bergamot (BEO) on gross behaviour and EEG power spectra recorded from the rat hippocampus and cerebral cortex. *Functional Neurology* 2009; 24(2):107–112.
  49. Saiyudthong S, Marsden CA. Acute effects of bergamot oil on anxiety-related behaviour and corticosterone level in rats. *Phytotherapy Research* 2011; 25(6):858–862.
  50. Rombolà L, Tridico L, Scuteri D, Sakurada T, Sakurada S, Mizoguchi H, Avato P, Corasaniti MT, Bagetta G, Morrone LA. Bergamot essential oil attenuates anxiety-like behaviour in rats. *Molecules* 2017; 22(4):614.
  51. Watanabe E, Kuchta K, Kimura M, Rauwald HW, Kamei T, Imanishi J. Effects of bergamot (*Citrus bergamia* [Risso] Wright & Arn.) essential oil aromatherapy on mood states, parasympathetic nervous system activity, and salivary cortisol levels in 41 healthy females. *Complementary Medicine Research* 2015; 22(1):43–49.
  52. Igarashi M, Ikei H, Song C, Miyazaki Y. Effects of olfactory stimulation with rose and orange oil on prefrontal cortex activity. *Complementary Therapies in Medicine* 2014; 22(6):1027–1031.
  53. Lehrner J, Marwinski G, Lehr S, Jöhren P, Deecke L. Ambient odors of orange and lavender reduce anxiety and improve mood in a dental office. *Physiology and Behaviour* 2005; 86(1–2):92–95.
  54. Faturi CB, Leite JR, Alves PB, Canton AC, Teixeira-Silva F. Anxiolytic-like effect of sweet orange aroma in Wistar rats. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 2010; 34(4):605–609.
  55. Costa CARA, Kohn DO, De Lima VM, Gargano AC, Flório JC, Costa M. The GABAergic system contributes to the anxiolytic-like effect of essential oil from *Cymbopogon citratus* (lemongrass). *Journal of Ethnopharmacology* 2011; 137(1):828–836.
  56. Blanco MM, Costa CARA, Freire AO, Santos JG, Costa M. Neurobehavioral effect of essential oil of *Cymbopogon citratus* in mice. *Phytomedicine* 2009; 16(2–3):265–270.
  57. Goes TC, Ursulino FRC, Almeida-Souza TH, Alves PB, Teixeira-Silva F. (2015). Effect of lemongrass aroma on experimental anxiety in humans. *Journal of Alternative and Complementary Medicine* 2015; 21(12):766–773.
  58. Kritsidima, M, Newton T, Asimakopoulou K. The effects of lavender scent on dental patient anxiety levels: A cluster randomised-controlled trial. *Community Dentistry and Oral Epidemiology* 2010; 38(1): 83–87.
  59. Bradley BF, Starkey NJ, Brown SL, Lea RW. Anxiolytic effects of *Lavandula angustifolia* odour on the Mongolian gerbil elevated plus maze. *Journal of Ethnopharmacology* 2007; 111(3):517–525.
  60. Uzunçakmak T, Alkaya AS. Effect of aromatherapy on coping with premenstrual syndrome: A randomized controlled trial. *Complementary Therapies in Medicine* 2018; 36:63–67.
  61. Hozumi H, Hasegawa S, Tsunenari T, Sanpei N, Arashina Y, Takahashi K, Konno A, Chida E, Tomimatsu S. Aromatherapies using *Osmanthus fragrans* oil and grapefruit oil are effective complementary treatments for anxious patients undergoing colonoscopy: A randomized controlled study. *Complementary Therapies in Medicine* 2017; 34:165–169.
  62. Shirzadegan R, Gholami M, Hasanvand S, Birjandi M, Beiranvand A. Effects of geranium aroma on anxiety among patients with acute myocardial infarction: A triple-blind randomized clinical trial. *Complementary Therapies in Clinical Practice* 2017; 29:201–206.
  63. Fakari RF, Tabatabaiechehr M, Kamali H, Fakari RF, Naseri M. Effect of inhalation of aroma of geranium essence on anxiety and physiological parameters during first stage of labor in nulliparous women: A randomized clinical trial. *Journal of Caring Sciences* 2015; 4(2): 135–141.
  64. Hajibagheri A, Babaii A, Adib-Hajbagheri M. Effect of *Rosa damascena* aromatherapy on sleep quality in cardiac patients: A randomized controlled trial. *Complementary Therapies in Clinical Practice* 2014; 20(3):159–163.
  65. Hongratanaworakit T. Relaxing effect of rose oil on humans. *Natural Product Communications* 2009; 4(2):291–296.
  66. De Almeida RN, Motta SC, De Brito Faturi C, Cattalani B, Leite JR. Anxiolytic-like effects of rose oil inhalation on the elevated plus-maze test in rats. *Pharmacology Biochemistry and Behaviour* 2004; 77(2):361–364.
  67. Bradley BF, Starkey NJ, Brown SL, Lea RW. The effects of prolonged rose odor inhalation in two animal models of anxiety. *Physiology and Behaviour* 2007; 92(5):931–938.
  68. Villareal MO, Ikeya A, Sasaki K, Arfa AB, Neffati M, Isoda H. Anti-stress and neuronal cell differentiation induction effects of *Rosmarinus officinalis* L. essential oil. *BMC*

- Complementary and Alternative Medicine 2017; 17(1):549.
69. Seol GH, Shim HS, Kim PJ, Moon HK, Lee KH, Shim I, Suh SH, Min SS. Antidepressant-like effect of *Salvia sclarea* is explained by modulation of dopamine activities in rats. *Journal of Ethnopharmacology* 2010; 130(1): 187–190.
70. Seol GH, Lee YH, Kang P, You JH, Park M, Min SS. Randomized controlled trial for *Salvia sclarea* or *Lavandula angustifolia*: Differential effects on blood pressure in female patients with urinary incontinence undergoing urodynamic examination. *Journal of Alternative and Complementary Medicine* 2013; 19(7): 664–670.
71. Shi A, Long Y, Ma Y, Yu S, Li D, Deng J, Wen J, Li X, Wu Y, He X, Hu Y, Li N, Hu Y. Natural essential oils derived from herbal medicines: A promising therapy strategy for treating cognitive impairment. *Frontiers in Aging Neuroscience* 2023; 15:1104269 (1-21).